EUCTR2004-002842-37-DE进行中（未招募）不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acne
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient has a diagnosis of mild to moderate facial acne vulgaris (up to 5 according to the Leeds revised acne grading system (O'Brien, Lewis, Cunliffe, 1998))
- •Patient has at least 20 inflammatory lesions (pustules, papules), at least 20 non-inflammatory lesions (open and closed comedones), and 3 or less nodules above the mandibular line
- •Patient is male or a surgically sterilised or post-menopausal female aged 16-40
- •Willingness to actively participate in the study and to come to the scheduled visits
- •Patient is capable of understanding the purpose and risks of the study, has been fully informed and has given written informed consent to participate in the study
- •Additionally for persons younger than 18 years: signed written informed consent of both legal guardians (not required for United Kingdom)
- •Willingness to discontinue the use of own cleansing and cosmetic products (e.g. soaps, creams, moisturizers and make-up) in the treatment area within 3 days before day 0 as well as during the course of the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to wash-out:
- •—Patient has used any of the following: tretinoin/isotretinoin within the last 12 months before baseline; Diane®/Dianette® within the last 3 months before baseline; any other anti-acne medication or any oral antibiotics within the last 28 days before baseline; over-the-counter topical acne preparations in the face within the last 14 days before baseline
- •—Topical therapy of the face in the last two weeks that may interfere with the aim of the study, e.g. corticosteroids
- •—Any systemic treatment or the intake of drugs interfering with the immune system (e.g. antiphlogistics, corticosteroids, immunosuppressants, and antihistamines) within 28 days before start of the study. This does not include minor pain relief medicine, like aspirin or acidamidophene if not more than 500 mg per day are used.
- •Patient has forms of facial acne other than acne vulgaris
- •Patient intends to grow a beard during the study
- •Moles, tattoos, pigmentation or scars on the face that would influence the visual assessment or lesion count
- •Patient has any medical condition or disorder that precludes him/her from participating in the study in the opinion of the investigator
- •Patient has a known allergy to components of the study drugs
- •Use of sunbeds or UV-treatment or intense sun exposure during the study period or within two weeks before baseline
- •Any history of drug addiction or alcoholism in the past 3 years
- •Infectious diseases (e.g. hepatitis or AIDS)
- •Patients with expected poor compliance
- •Participation in a clinical trial concomitantly or within the last 30 days prior to the start of this study
- •Patient has been previously randomised in this study
- •Employees of the study sites or of the sponsor company
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acneEUCTR2004-002842-37-GBFujisawa GmbH66
已完成
3 期
A randomized, double-blind, vehicle-controlled, parallel-group trial to assess the efficacy, safety and tolerability of P-3073 for topical treatment of nail psoriasisPsoriasis vulgarisail PsoriasisL40.0DRKS00009547Polichem SA378
已完成
不适用
A randomized, vehicle-controlled, double-blind, Phase I/IIa, multiple-dose, multiple-cohort, Proof of Concept study in Healthy Volunteers and Patients with Cutaneous T-cell Lymphoma to characterize the safety, efficacy, and pharmacodynamics of topical bimiralisibblood cancer affecting the skin10025321NL-OMON48135Piqur Therapeutics AG24
进行中（未招募）
2 期
GuARD - GR1014 cutaneous gel Against Radiation DermatitisRadiodermatitis occurring with adjuvant radiotherapy for localised breast cancer after lumpectomySkin and Connective Tissue DiseasesISRCTN61697120Graegis Pharmaceuticals Ltd273
进行中（未招募）
不适用
A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderate atopic dermatitisatopic dermatitisEUCTR2004-002594-23-DEWeber & Weber GmbH & Co.KG